Navigation Links
iCo Therapeutics Closes $1.3 Million Private Placement
Date:2/9/2009

VANCOUVER, Feb. 9 /PRNewswire-FirstCall/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce the completion of a $1,292,500 non-brokered private placement. This financing provides the company with sufficient capital to develop iCo-007 through to the completion of the Phase 1 clinical trial. iCo-007 is targeting the treatment of Diabetic Macular Edema. The balance of funds will provide the company with additional working capital. iCo's partner Isis Pharmaceuticals Inc., (NASDAQ: ISIS), participated as a lead investor in the financing, along with select insiders and existing shareholders.

"We are pleased to be able to invest in the advancement of iCo-007, a promising drug in our pipeline being developed with the ocular disease expertise of our partners at iCo," said B. Lynne Parshall, COO and CFO of Isis Pharmaceuticals. "This funding will help move iCo-007 to a key value inflection point by supporting completion of the ongoing study in patients with diffuse macular edema. iCo-007 is a product of our satellite company strategy to exploit antisense technology beyond our core areas of focus to provide new treatment options in a broad range of diseases. With the benefit of our strong financial position, strengthening our pipeline in a variety of ways is a key strategic imperative. This transaction represents one step toward achieving that goal."

The private placement represents 6,462,500 common shares and 3,231,250 million warrants. Each warrant will entitle the holder, on exercise, to purchase one additional Common Share at a price of $0.30 at any time prior to the date 12 months following the closing date. The closing of the first tranche of this placement, in the amount of $582,750, was announced on January 30th, 2009.

A finder's fee of 7% will be payable to certain arm's length third parties with respect to a portion of the private pl
'/>"/>

SOURCE iCo Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
3. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
4. Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share
5. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
6. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
7. Omnitura Therapeutics Announces Private Placement Financing
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. Cell Therapeutics Receives Additional NASDAQ Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... MN , May 1, 2015 /PRNewswire/ - BioAmber ... producing sustainable chemicals, today announced that it has priced an ... stock at a price of $9.00 per share, and ... to purchase up to an additional 585,000 shares of ... will be $35.1 million.  The offering is expected to close ...
(Date:5/1/2015)... , May 1, 2015 ... Genetic Technologies Ltd (NASDAQ: GENE ), Agilent ... Scientific Inc. (NYSE: TMO ), Sequenom Inc. ... PKI ). Free research report on Genetic ... On Thursday, April 30, 2015, the NASDAQ Composite ...
(Date:4/30/2015)... Blythewood, South Carolina (PRWEB) May 01, 2015 ... steam system services, is extremely proud to announce that ... have been named as a winner of a Queen’s ... business success for the design and manufacture of a ... is the revolutionary alternative to traditional steam flow ...
(Date:4/30/2015)... - BioAmber Inc. (NYSE: BIOA ), an industrial ... commenced an underwritten public offering of its common stock.  ... 30-day option to purchase up to an additional 15 ... the public offering. The offering is subject to market ... whether or when the offering may be completed, or ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... Multiple Fields, Strengthening the Molecular Bioassays Market , ... Based on its recent analysis of the molecular ... with the 2009 Frost & Sullivan North America ... pioneering Tag-lite(TM) technology for cell surface receptor investigation, ...
... , PHILADELPHIA and LONDON, June 9 /PRNewswire/ -- ... reported today that, despite difficult economic times, renewals of ... many existing customers have even added new content to ... is the world,s largest citation database, providing researchers, administrators, ...
... Executive to Lead Personalized Medicine Company in Next Phase of Growth ... , a personalized medicine company, announced today ... new President and CEO. , , Burns comes to ... strategic management of science and technology for pharmaceutical, diagnostic, and biotech ...
Cached Biology Technology:Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 2Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 3Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 4Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 5Web of Science(R) Renewals Remain Strong Despite Tough Economic Climate 2AssureRx Adds New CEO 2
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... occur in sports and in combat, but health experts ... head movements during these activities pose the greatest risks ... have developed a powerful new computer-based process that helps ... injuries. This approach could lead to new medical treatment ...
... 12, 2013The foodborne bacteria Listeria monocytogenes sickens ... many more worldwide, killing about 25-30% of those infected. ... L. monocytogenes , and current methods for detecting the ... method for developing an inexpensive biosensor to detect the ...
... maxillary sinuses. Those bulbous pouches on either side of the ... sinus infections than anything else. They were thought to be ... present value. Yet researchers led by the University of ... role in the shape and function of the human nose, ...
Cached Biology News:Computer model may help athletes and soldiers avoid brain damage and concussions 2Computer model may help athletes and soldiers avoid brain damage and concussions 3Low-cost nano-biosensor to detect foodborne pathogen that causes listeriosis 2Low-cost nano-biosensor to detect foodborne pathogen that causes listeriosis 3The nose's unheralded neighbor 2The nose's unheralded neighbor 3